vTv Therapeutics (VTVT) Retained Earnings (2016 - 2025)
Historic Retained Earnings for vTv Therapeutics (VTVT) over the last 11 years, with Q3 2025 value amounting to -$319.6 million.
- vTv Therapeutics' Retained Earnings fell 793.65% to -$319.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.6 million, marking a year-over-year decrease of 793.65%. This contributed to the annual value of -$299.7 million for FY2024, which is 664.53% down from last year.
- As of Q3 2025, vTv Therapeutics' Retained Earnings stood at -$319.6 million, which was down 793.65% from -$310.9 million recorded in Q2 2025.
- vTv Therapeutics' Retained Earnings' 5-year high stood at -$247.7 million during Q1 2022, with a 5-year trough of -$319.6 million in Q3 2025.
- In the last 5 years, vTv Therapeutics' Retained Earnings had a median value of -$280.8 million in 2023 and averaged -$279.7 million.
- In the last 5 years, vTv Therapeutics' Retained Earnings soared by 1420.58% in 2021 and then crashed by 1085.89% in 2023.
- vTv Therapeutics' Retained Earnings (Quarter) stood at -$248.8 million in 2021, then decreased by 6.71% to -$265.5 million in 2022, then dropped by 5.84% to -$281.0 million in 2023, then dropped by 6.65% to -$299.7 million in 2024, then dropped by 6.63% to -$319.6 million in 2025.
- Its last three reported values are -$319.6 million in Q3 2025, -$310.9 million for Q2 2025, and -$304.8 million during Q1 2025.